Using Arbidol to treat allergic rhinitis
Official title: Study on the Efficacy and Safety of Oral Administration of Arbidol in the Treatment of Allergic Rhinitis Patients
Run by Huazhong University of Science and Technology · NCT06462417 · Data updated 2026-11-12
This study is testing if Arbidol, a medicine usually used for the flu, can help people with allergic rhinitis feel better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Wuhan, Hubei and 1 other locations) |
| Status | Recruiting |
| Started | July 11, 2024 |
| Main results expected | June 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | May 7, 2025 |
| Trial ID | NCT06462417 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with allergic rhinitis who exhibit moderate to severe nasal symptoms.
✕Probably not a fit
Patients with mild allergic rhinitis or those not meeting the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study explores the efficacy and safety of Arbidol, a medication traditionally used for influenza, in treating allergic rhinitis. Allergic rhinitis is a chronic inflammatory condition of the nasal mucosa that significantly affects patients' quality of life. The research aims to determine if Arbidol can inhibit molecular targets involved in the disease's pathogenesis, potentially providing a new treatment option. Participants will be evaluated based on their nasal symptoms and adherence to the study protocol.
Why it matters
Potential benefit: If successful, this treatment could offer a new effective option for patients suffering from allergic rhinitis.
How similar studies have gone: While the use of Arbidol for allergic rhinitis is novel, previous studies have shown its effectiveness in other conditions, suggesting potential for success in this application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patients with allergic rhinitis (in line with the diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin)" formulated by the Rhinology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association). * 2\. At least 2 nasal symptoms are moderate or above (referring to sneezing, runny nose, nasal itching, nasal congestion with at least 2 symptoms ≥2 points). * 3\. Female subjects are not pregnant or lactating and have no pregnancy and lactation plans during the trial medication period. * 4\. The subject has not participated in other clinical trials in the previous three months and agrees not to participate in other clinical trials before reaching the endpoint of this trial. * 5\. The subject/legally authorized representative understands the purpose and procedures of the trial and voluntarily signs the informed consent form, voluntarily participates in the study and complies with the study regulations, understands and complies with the medication dosage and follow-up plan, and correctly records the scale score, the number of medications, concomitant medication and adverse event records. Exclusion Criteria: * 1\. Who are allergic to Arbidol. * 2\. Patients with abnormal liver and kidney function (ALT and AST exceed the maximum limit of normal value by 1.5 times, and Cr exceeds the upper limit of normal value). * 3\. Patients with abnormal ECG parameters and clinically significant (PR\>220ms, QRS\>120ms, QTc\>450ms) and bradycardia. * 4\. Patients with severe asthma or acute asthma exacerbations. * 5\. Patients with structural heart disease, severe hypertension (blood pressure greater than 180/110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness. Patients with structural heart disease, severe hypertension (blood pressure greater than 180/110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness. * 6\. Patients with nasal polyps, severe deviated nasal septum, sinusitis, and hypertrophic rhinitis. * 7\. Who have participated in other clinical studies within 3 months. * 8\. Women are pregnant or lactating, in childbearing age with positive blood pregnancy test, or have pregnancy and lactation plans during the trial medication. * 9\. Drug abuse and alcoholism. * 10\. Who have received allergen-specific immunotherapy within 3 years. * 11\. Positive infectious disease screening (hepatitis B surface antigen, hepatitis C antibody, AIDS antibody and treponema pallidum antibody). * 12\. Who should not be included if there are other reasons in the opinion of the investigator.
Where it's running
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China Recruiting -
Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Zheng Liu, Doctor
- Email: zhengliuent@hotmail.com
- Phone: 86 027 83663807
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mannan-Conjugated Allergoids for House Dust M mite Allergy
A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.
-
Mannan-conjugated Allergoids for House Dust Mite Allergy
A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.
-
Dog-allergy immunotherapy with Alutard SQ Dog in Swedish practice
This study tests whether Alutard SQ Dog immunotherapy helps adults with moderate-to-severe dog allergy when used in real-world Swedish care.
-
PL-14 Allergy Blocker vs saline spray for seasonal nasal allergies
This study tests whether PL-14 Allergy Blocker, a drug-free nasal gel, reduces nasal allergy symptoms in adults with seasonal allergic rhinitis compared with saline spray.
-
Helping decide between nasal surgery options for chronic hypertrophic rhinitis
A randomized trial will see if a printed patient decision aid helps adults with chronic hypertrophic rhinitis choose between surgical options more confidently and with less regret.
-
Digital app to improve adherence to aeroallergen immunotherapy
This project will test whether a smartphone app can help people with allergic rhinitis keep taking their prescribed aeroallergen immunotherapy for the full treatment course.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.